Senseonics Holdings, Inc. (SENS)

Senseonics' stock price has experienced significant changes, with a decline of 63.63% over the past year and an average weekly change of 12% over the past three months. Shareholder dilution is a major risk, with a 52% increase in shares outstanding over the past year. Recent financial events include raising $92 million in gross proceeds through a public equity offering and expanding its Hercules Capital debt facility to $140 million, resulting in $55 million of total debt outstanding as of March 31, 2026. Senseonics reported strong Q1 2026 revenue of $11.7 million, an 85% year-over-year increase, and raised its full-year 2026 global net revenue guidance to $60 million to $64 million, representing a projected year-over-year growth of 70% to 82%.

Senseonics' business experiences seasonality in demand, with approximately 40% of its 2026 sales expected in the first half of the year and the remaining 60% in the second half. This seasonality is attributed to the resetting of patient deductibles at the beginning of the calendar year and increased utilization of patient assistance programs during that time.

Senseonics Holdings, Inc. specializes in developing and manufacturing continuous glucose monitoring (CGM) systems, with its core business revolving around the Eversense brand of implantable CGM systems, including Eversense, Eversense XL, Eversense E3, and Eversense 365. These systems measure glucose levels through an under-the-skin sensor, communicating with a smart transmitter and mobile application for real-time diabetes monitoring and management. The Eversense 365 system is the first and only one-year wear CGM, offering extended accuracy and integration with automated insulin delivery (AID) systems. The company distributes its products through a network of distributors and strategic partners.

Senseonics Holdings, Inc. has a geographic footprint that includes the United States and international markets. The company has received CE Mark approval, enabling it to distribute the Eversense system across various European markets. In early 2026, Eversense 365 launched in Europe, with initial patients in Sweden and planned launches in Germany, Spain, and Italy.

Senseonics has focused on the commercialization and expansion of its Eversense 365 CGM system, with the first European launch in April 2026, following CE Mark approval in January. Real-world evidence studies have demonstrated the sustained performance and positive impact of Eversense 365. The company's direct-to-consumer (DTC) marketing efforts have led to a nearly 100% year-over-year increase in new patient shipments through this channel in Q1 2026. Senseonics also completed the full integration of its U.S. commercial team from Ascensia by January 1, 2026.

Senseonics Holdings, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors hold approximately 9.65% to 17.43% of the company's stock. Insiders own about 12.37%, and public companies and individual investors hold approximately 77.99%. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., Geode Capital Management, Llc, UBS Group AG, and Goldman Sachs Group Inc. Timothy Goodnow, the President and CEO, is also a significant individual shareholder.